Eurofins Discovery, a provider of services and products to the drug discovery industry, has formed a collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will use Eurofins Discovery’s DiscoveryOne offering, an integrated drug discovery platform providing support to progress programs to preclinical development and beyond.
 
Amphilix will engage Eurofins Discovery to prosecute the biology, pharmacology, ADME, and safety pharmacology aspects of the program, working in collaboration with the team at Eurofins Discovery to progress to a development candidate. The two organizations expect this to be the first of multiple programs in which they collaborate to discover new treatments for unmet medical needs.